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TO THE EDITOR
Sensitive skin is deﬁned as an exagger-
ated reaction to environmental factors,
characterized by prickling, burning,
itching, stinging, pain, or tingling sensa-
tion (Berardesca et al., 2006; Farage and
Maibach, 2010). Recently, in addition
to a previous notion that sensitive skin is
associated with increased neurosensory
responses, impaired skin barrier funct-
ion, and altered immune responsiveness
(Ständer et al., 2009), we discovered
that sensitive skin is closely associated
with the dysfunction of muscle contrac-
tion, carbohydrate and lipid metabo-
lism, and ion balance, by using an
unbiased microarray analysis of skin
samples obtained from subjects with
sensitive or non-sensitive skin (Kim
et al., 2014). However, the critical regu-
lator implicated in the pathogenesis of
sensitive skin remains still elusive.
Previous microarray ﬁndings suggest
that adiponectin (ADIPOQ) is one of the
downregulated genes in sensitive skin
(Kim et al., 2014). ADIPOQ is an
adipocyte-derived adipokine with multi-
ple salutary effects such as anti-apopto-
tic, anti-inﬂammatory, and anti-oxidative
activities, as well as anti-obesity and
anti-insulin resistance roles in diverse
organs and cells including skeletal mus-
cles, liver, and adipose tissues (Goldstein
and Scalia, 2004). Particularly, ADIPOQ
is known to regulate muscle phenotypes
and functions (Krause et al., 2008).
ADIPOQ induces vascular smooth
muscle cell differentiation, suppresses
triglyceride accumulation, and stimu-
lates fatty acid oxidation and glucose
uptake in myocytes (Yamauchi et al.,
2002).
Healthy volunteers who perceived
their skin to be ‘sensitive’ or ‘non-
sensitive’ were recruited. Sensitive skin
individuals were identiﬁed based on
questionnaires and a 10% lactic acid
stinging test as previously described
(Farage and Maibach, 2010; Kim et al.,
2014). Those with underlying skin
diseases such as atopic dermatitis,
contact dermatitis, and rosacea were
excluded. This study was approved by
the Institutional Review Board at Seoul
National University Hospital and con-
ducted according to the Declaration of
Helsinki. All subjects provided written
informed consent. We found that
the expression of ADIPOQ mRNA
(Figure 1a) and protein (Figures 1b
and c, as shown by Western blot
and immunoﬂuorescence staining,
respectively) was markedly downregu-
lated in sensitive skin tissues, in com-
parison with non-sensitive skin tissues.
ADIPOQ binds to ADIPOQ receptor 1
(ADIPOR1) and ADIPOQ receptor 2
(ADIPOR2) and activates 5′-AMP-acti-
vated protein kinase (AMPK). AMPK is a
master regulator of glucose and lipid
metabolism and is activated by various
cellular stresses, physiologic stimuli
such as muscle contraction, and hor-
mones such as ADIPOQ (Hardie et al.,
2006; Ruderman et al., 2013). ADIPOQ
regulates peripheral and whole-body
energy metabolism via controlling
AMPK activity (Sattar and Sattar,
2012). Expression of ADIPOR1/2 was
reduced in sensitive skin (Figure 1d). In
addition, the level of phospho-AMPK
was markedly decreased in sensitive
skin tissues, whereas the total AMPK
level remained unchanged (Figure 1e).
These results suggest that decreased
expression of ADIPOQ and its recep-
tors, accompanied by low AMPK activ-
ity, is implicated in the development of
sensitive skin.
To examine the contributory role of
ADIPOQ in the pathogenesis of sensi-
tive skin, we performed small interfering
RNA (siRNA)-mediated knockdown of
the ADIPOQ gene in vitro. Our previous
in vivo results obtained in sensitive skin
tissues suggest that decreased synthesis
of ATP and lower pH cause abnormal
muscle contraction and skin sensitivity
(Kim et al., 2014). Thus, we examined
transcript and physiologic changes in
human rhabdomyosarcoma (RD) cells,
as an in vitro model of human skeletal
muscle, transfected with ADIPOQ
siRNA. Intriguingly, transient transfec-
tion of ADIPOQ siRNA into RD cells
recapitulated the distinct gene express-
ion signature related to muscle
composition, carbohydrate and lipid
metabolism, and ion balance
(Figure 2a), as previously described in
human sensitive skin in vivo (Kim et al.,
2014). ATP amount was also
signiﬁcantly decreased in ADIPOQ
siRNA–treated RD cells as measured
using the ENLITEN ATP Assay System
Bioluminescence Detection Kit
(Promega, Madison, WI; Figure 2b). To
measure intracellular pH, cells were
incubated with 4 μM BCECF AMAccepted article preview online 16 April 2015; published online 14 May 2015
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(Invitrogen, Life Technologies, Carls-
bad, CA) or 5 μM SNARF-1 AM (Invitro-
gen), intracellular pH indicators. In
comparison with control siRNA–trans-
fected cells, ADIPOQ siRNA–trans-
fected RD cells showed a much lower
pH after the lactic acid challenge
(Figure 2c) but higher expression of
pain-related transcripts such as transient
receptor potential cation channel sub-
family V member 1 (TRPV1), acid sen-
sing ion channel 3 (ASIC3), and
calcitonin gene–related peptide (CGRP;
Figure 2d), which is consistent with
human sensitive skin in vivo (Kim et al.,
2014). More speciﬁcally, we demon-
strated that sensitive skin is closely
associated with impaired acidic
homeostasis and pain provocation via
TRPV1, ASIC3, and CGRP. Tissue
acidosis elicits pain via TRPV1, ASIC3,
and CGRP (Holzer, 2009). Although
ASICs are the main mediators of pain
caused by moderate acidity, TRPV1,
along with ASICs, contributes to pain
elicited by more severe acidiﬁcation
(Holzer, 2009; Deval et al., 2010).
When these nociceptors are activated,
several neuropeptides such as substance
P and CGRP are released, and pain
develops (Reeh and Kress, 2001). Next,
we examined whether exogenous
administration of ADIPOQ could rescue
these alterations. Indeed, treatment of
RD cells with ADIPOQ induced a
substantial reduction in expressions of
TRPV1, ASIC3, and CGRP, which were
increased by knockdown of ADIPOQ
(Figure 2d), suggesting a potential ther-
apeutic role of ADIPOQ supplementa-
tion for sensitive skin. Moreover, in A7r5
muscle cells, which can contract in
response to phorbol esters (Dykes et al.,
2003), ADIPOQ knockdown induced
aberrant muscle contraction, characteri-
zed by loss of ﬁber structure and the
formation of peripheral bodies
throughout the interval of contraction,
even in the vehicle-treated state, as well
as following phorbol-12,13-dibutyrate
stimulation (Figure 2e).
Disruption of metabolic homeostasis
can cause variable diseases such as
obesity, diabetes, and the metabolic
syndrome, which are closely associated
with reduced ADIPOQ production
(Kadowaki et al., 2006). Here, we
demonstrated that sensitive skin is also
linked to ADIPOQ deﬁciency and
ensuing metabolic alterations. The
reduced expression of ADIPOQ and
corresponding receptors and the
mitigation of AMPK activity in
sensitive skin might be responsible for
the downregulation of genes involved in
carbohydrate and fat metabolism, and
decreased ATP content and pH, which
could induce dysfunction of muscle
contraction, and pain sensation in
sensitive skin (Figure 2f).
Little is known about the relationship
between sensitive skin and metabolic
disorders such as obesity, diabetes, and
the metabolic syndrome. Reduced ADI-
POQ production in sensitive skin may
inﬂuence metabolic disorders or vice
versa. If and how obesity, diabetes, and
the metabolic syndrome are associated
with sensitive skin need to be eluci-
dated in future studies. To better under-
stand the implications of ADIPOQ in
sensitive skin, further genetic or pro-
spective studies are needed to address
whether reduced ADIPOQ production
is an inherited or acquired abnormality.
Moreover, as the cellular location of
ADIPOQ and its receptors has not been
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Figure 1. Conﬁrmation of adiponectin (ADIPOQ) gene expressions in sensitive skin. Sensitive (S) and non-sensitive (NS) human skin samples were obtained
from facial malar prominence or buttock after 10% lactic acid or normal saline (vehicle) application. ADIPOQ genes in sensitive skin were conﬁrmed by (a) real-
time PCR (n= 5), (b) western blot analysis (n=3), or (c) immunoﬂuorescent staining (n=3). (d) Expression of adiponectin receptor 1 or 2 (ADIPOR1/2). All real-
time PCR data represent mean± SEM of the ratio between each gene and 36B4. ADIPOR1 (n= 3) and ADIPOR2 (n=5); *Po0.05, **Po0.01, and ***Po0.001.
(e) Activation of 5′-AMP-activated protein kinase (AMPK). Another set of sensitive human skin samples and non-sensitive human skin samples was obtained from
the buttock skin, and proteins were isolated. Western blot analysis was performed using antibodies against phosphor-AMPKα (Thr172) and total-AMPK. As a
control, the level of β-actin was determined using an antibody for β-actin (n= 3).
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precisely determined in the skin, the
roles of ADIPOQ need to be examined
in other contributory cells, as well as in
other sensitive skin diseases such as
atopic dermatitis. Finally, successful
reversal of the aforementioned aberra-
tions with ADIPOQ treatment raises
the possibility of therapeutic ADIPOQ
stimulation in sensitive skin. Further
preclinical and clinical studies are
warranted to conﬁrm its role in the
treatment of sensitive skin in vivo.
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Figure 2. Adiponectin (ADIPOQ) is responsible for characteristic gene expression and physiologic alterations in sensitive skin. (a) Alterations of gene
expression (n=5), (b) ATP contents (n=3), and (c) intracellular pH in response to knockdown of ADIPOQ in human rhabdomyosarcoma (RD) muscle cells. RD
cells were incubated with 4 μM BCECF AM or 5 μM SNARF-1 AM, intracellular pH indicators. The ﬂuorescence intensity was measured under 50mM lactic acid
treatment. (d) Expression of TRPV1, ASIC3, and CGRP mRNA. Human RD striated muscle cells were transfected with ADIPOQ-siRNA or scrambled siRNA (NC).
Besides, transfected cells were treated with recombinant ADIPOQ (100 ngml−1) or vehicle. TRPV1 (n=5), ASIC3 (n= 3), and CGRP (n=3). *Po0.05, **Po0.01
versus the NC group. †Po0.05 versus the small interfering RNA (siRNA)-treated group. Data represent mean± SEM of the ratio between each gene and 36B4. (e)
Alteration of muscle contraction. A7r5 cells underwent RNA interference and were subsequently treated with 10−7M phorbol-12,13-dibutyrate (PDBu) for
30 minutes. (f) A schematic model of metabolic pathway leading from reduced ADIPOQ to sensitive skin.
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TO THE EDITOR
The molecular events underlying the
oncogenesis of cutaneous T-cell lym-
phomas (CTCLs) remain largely
unknown, especially when considering
primary or driver mutations. Global
genomic approaches have revealed the
existence of recurrent chromosomal
or genetic alterations, some of which
having potential diagnosis or prognosis
value (Scarisbrick et al., 2000; Vermeer
et al., 2008; van Doorn et al., 2009;
Laharanne et al., 2010a, 2010b;
Cristofoletti et al., 2013). However,
no speciﬁc gene mutation is currently
assessed for the management of patients
with CTCLs.
Vaque et al. (2014) recently identiﬁed
somatic mutations of the Phospholipase
C Gamma 1 (PLCG1) gene in about
20% of epidermotropic CTCLs, being
notably more frequent in transformed/
tumoral mycosis fungoides (T-MF; 8/30
cases) and the Sézary syndrome (SS; 1/2
cases) than in erythrodermic and
folliculotropic mycosis fungoides (1/20
cases). They reported a c.1034C4T/p.
S345F mutation in exon 11 in nine
patients (eight T-MF and one SS) and a
c.1559C4T/p.S520F mutation in exon
15 (in one erythrodermic mycosis fungo-
ides case). Such mutations, especially the
p.S345F mutation, conferred enhanced
signaling capacity and transforming
property. Finally, PLCG1 mutations were
suggested to be possibly associated with a
higher rate of disease-related death
(Vaque et al., 2014).
These ﬁndings prompted us to inves-
tigate the PLCG1 gene status in our
series of CTCLs, including T-MF (n= 37)
and SS (n= 39). We also studied other
CTCL subtypes including lymphomatoid
papulosis (LyP; n= 4), cutaneous ana-
plastic large cell lymphomas (c-ALCL,
n= 14), and the following T cell or
CTCL cell lines: MyLa, SeAX, HH,
Hut78, FEPD, and 1301 (for origin see
Chevret et al. (2014)).
All cases were retrieved from the
Aquitaine database of cutaneous
See related commentary on pg 2153
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